ClinicalTrials.gg
CompletedNCT02573311Updated Apr 8, 2020Results posted

Actual Use Study of Tamsulosin in Men

A Phase 3 interventional study of tamsulosin hydrochloride in Urological Manifestations, sponsored by Boehringer Ingelheim. Completed at 40 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-08.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,117
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

An actual use study to assess how men who respond to advertisements about urinary symptoms use tamsulosin in a simulated Over the Counter (OTC) setting including following "stop use and ask a doctor if" and "ask a doctor before use" statements and if they take the medication according to the label instructions, also assess any reported adverse events during simulated OTC use.

02

Conditions studied

  • Urological Manifestations
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men, 18 years of age and older, with bothersome urinary symptoms
  • Able to speak, read and understand English
  • Subject or anyone in their household is not currently employed by a marketing or marketing research company, advertising agency or public relations firm, a pharmacy or pharmaceutical company, a manufacturer of medicines, a managed care or health insurance company, as a certified or licensed healthcare professional or in a healthcare practice
  • Has not participated in any clinical trial in the last 12 months
  • Willing to sign an /HIPPA form and willing and able to provide contact information

Exclusion criteria

Exclusion criteria:

  • Allergy to tamsulosin hydrochloride or sulpha drugs
  • Report current use of a medication listed on the "Do not use" section of the Drug Facts Label (DFL)
  • Choose not to purchase the study product
  • Do not provide consent or sign HIPPA form
  • Do not provide contact information
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,117 participants (actual)

Study arms

  • Experimental
    men

    Drug: tamsulosin hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact With Doctor Out of Total Population in Cohort 1

    Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the Drug Facts Label (DFL) within the first 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population is presented along with 95% exact two sided Clopper-Pearson confidence interval.

    Time frame: 12 weeks

Secondary outcomes

  1. Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL During the Study (24 Weeks) and do Not Stop Use or Initiate Contact With a Doctor Out of the Total Population in Cohort 1

    Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL during the study (i.e., 24 weeks) and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.

    Time frame: 24 weeks

  2. Percentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 12 Weeks

    Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 12 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.

    Time frame: Week 12

  3. Percentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 24 Weeks

    Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 24 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 24 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.

    Time frame: Week 24

  4. Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product Out of the Total Population in Cohort 1

    Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within the first 12 weeks of using the study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval

    Time frame: 12 weeks

  5. Percentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population in Cohort 1

    Percentage of men who reported at baseline a symptom or condition under the "Ask A Doctor Before Use" section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.

    Time frame: 24 weeks

  6. Percentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population of Cohort 1 Who Report a Symptom or Condition

    Percentage of men who reported at baseline a symptom or condition under the "Ask A Doctor Before Use" section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 who reported a symptom or condition is presented along with 95% exact two sided Clopper-Pearson confidence interval.

    Time frame: 24 weeks

  7. Percentage of Men Who Seek the Advice of a Physician Within the First 12/24 Weeks of the Study Out of the Total Population in Cohort 1

    Percentage of men who sought advice of a physician within the first 12/24 weeks of the study out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval

    Time frame: Week 12 and Week 24

  8. Percentage of Men Who Took Two or More Capsules Per Day Within the First 12/24 Weeks of Using Study Product Out of the Total Population in Cohort 1

    Percentage of men who took two or more capsules per day within the first 12/24 weeks of using study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval

    Time frame: Week 12 and Week 24

07

Results

Posted Apr 8, 2020

Participant flow

Disposition for Part 1
Participant flow — Disposition for Part 1
MilestoneCohort 1Cohort 2
Started1737364
Completed1730361
Not completed73
Withdrew: Withdrawal by subject73
Disposition for Part 2
Participant flow — Disposition for Part 2
MilestoneCohort 1Cohort 2
Started964153
Completed754127
Not completed21026
Withdrew: Physician decision257
Withdrew: Adverse event365
Withdrew: Lost to follow-up767
Withdrew: Withdrawal by subject603
Withdrew: Investigator decision01
Withdrew: Other than specified above133

Outcome measures

PrimaryPercentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact With Doctor Out of Total Population in Cohort 1

Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the Drug Facts Label (DFL) within the first 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population is presented along with 95% exact two sided Clopper-Pearson confidence interval.

Time frame:
12 weeks
Reported as:
Number · Percentage of participants
Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact With Doctor Out of Total Population in Cohort 1
Percentage of participantsCohort 1
Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact With Doctor Out of Total Population in Cohort 10.2 (0.0 to 0.8)
SecondaryPercentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL During the Study (24 Weeks) and do Not Stop Use or Initiate Contact With a Doctor Out of the Total Population in Cohort 1

Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL during the study (i.e., 24 weeks) and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.

Time frame:
24 weeks
Reported as:
Number · Percentage of participants
Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL During the Study (24 Weeks) and do Not Stop Use or Initiate Contact With a Doctor Out of the Total Population in Cohort 1
Percentage of participantsCohort 1
Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL During the Study (24 Weeks) and do Not Stop Use or Initiate Contact With a Doctor Out of the Total Population in Cohort 10.2 (0.0 to 0.8)
SecondaryPercentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 12 Weeks

Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 12 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 12 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 12 Weeks
Percentage of participantsCohort 1
Percentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 12 Weeks1.0 (0.1 to 3.4)
SecondaryPercentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 24 Weeks

Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 24 weeks of using study product and did not stop use or initiated contact with a doctor out of the total population of men in Cohort 1 who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within 24 weeks of using study product is presented along with 95% exact two sided Clopper-Pearson confidence interval.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 24 Weeks
Percentage of participantsCohort 1
Percentage of Men Who Report Condition Listed Under "Stop Use and Ask a Doctor if" Section of the DFL and do Not Stop Use or Initiate Contact With Doctor Out of the Total Population in Cohort 1 Who Report the Condition Within 24 Weeks0.9 (0.1 to 3.3)
SecondaryPercentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product Out of the Total Population in Cohort 1

Percentage of men who reported a condition listed under the "Stop use and ask a doctor if" section of the DFL within the first 12 weeks of using the study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval

Time frame:
12 weeks
Reported as:
Number · Percentage of participants
Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product Out of the Total Population in Cohort 1
Percentage of participantsCohort 1
Percentage of Men Who Report a Condition Listed Under the "Stop Use and Ask a Doctor if" Section of the DFL Within the First 12 Weeks of Using Study Product Out of the Total Population in Cohort 122.4 (19.8 to 25.2)
SecondaryPercentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population in Cohort 1

Percentage of men who reported at baseline a symptom or condition under the "Ask A Doctor Before Use" section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval.

Time frame:
24 weeks
Reported as:
Number · Percentage of participants
Percentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population in Cohort 1
Percentage of participantsCohort 1
Percentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population in Cohort 120.3 (17.8 to 23.1)
SecondaryPercentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population of Cohort 1 Who Report a Symptom or Condition

Percentage of men who reported at baseline a symptom or condition under the "Ask A Doctor Before Use" section of the DFL and initiated contact with a doctor out of the total population of men in Cohort 1 who reported a symptom or condition is presented along with 95% exact two sided Clopper-Pearson confidence interval.

Time frame:
24 weeks
Reported as:
Number · Percentage of participants
Percentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population of Cohort 1 Who Report a Symptom or Condition
Percentage of participantsCohort 1
Percentage of Men Who Report at Baseline a Symptom or Condition Under the "Ask A Doctor Before Use" Section of the DFL and Initiate Contact With a Doctor Out of the Total Population of Cohort 1 Who Report a Symptom or Condition84.3 (78.9 to 88.8)
SecondaryPercentage of Men Who Seek the Advice of a Physician Within the First 12/24 Weeks of the Study Out of the Total Population in Cohort 1

Percentage of men who sought advice of a physician within the first 12/24 weeks of the study out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval

Time frame:
Week 12 and Week 24
Reported as:
Number · Percentage of participants
Percentage of Men Who Seek the Advice of a Physician Within the First 12/24 Weeks of the Study Out of the Total Population in Cohort 1
Percentage of participantsCohort 1
Week 12 (N=924)43.1 (39.9 to 46.3)
Week 24 (N=924)56.4 (53.1 to 59.6)
SecondaryPercentage of Men Who Took Two or More Capsules Per Day Within the First 12/24 Weeks of Using Study Product Out of the Total Population in Cohort 1

Percentage of men who took two or more capsules per day within the first 12/24 weeks of using study product out of the total population of men in Cohort 1 is presented along with 95% exact two sided Clopper-Pearson confidence interval

Time frame:
Week 12 and Week 24
Reported as:
Number · Percentage of participants
Percentage of Men Who Took Two or More Capsules Per Day Within the First 12/24 Weeks of Using Study Product Out of the Total Population in Cohort 1
Percentage of participantsCohort 1
Week 12 (N=924)7.6 (6.3 to 10.0)
Week 24 (N=924)9.5 (8.1 to 12.1)

Adverse events

Collected over From the first drug administration until 3 days after the treatment phase, up to 171 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1—54/927 (5.8%)61/927 (6.6%)
Cohort 2—12/150 (8%)25/150 (16.7%)
Cohort 1 and 2—66/1,077 (6.1%)86/1,077 (8%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventCohort 1Cohort 2Cohort 1 and 2
Coronary artery diseaseCardiac disorders1/9271/1502/1077
Coronary artery occlusionCardiac disorders1/9271/1502/1077
Myocardial infarctionCardiac disorders2/9271/1503/1077
Chest painGeneral disorders2/9271/1503/1077
HypersensitivityImmune system disorders0/9271/1501/1077
CellulitisInfections and infestations0/9271/1501/1077
PneumoniaInfections and infestations1/9271/1502/1077
Respiratory tract infectionInfections and infestations0/9271/1501/1077
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/9271/1501/1077
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/9271/1501/1077
Most frequent other events
Most frequent other events
EventCohort 1Cohort 2Cohort 1 and 2
NasopharyngitisInfections and infestations48/92717/15065/1077
Back painMusculoskeletal and connective tissue disorders15/9278/15023/1077

Baseline characteristics

Analysis Set for Cohort 1 and 2: This set included all men who were currently not using a prescription medicine for BPH (Cohort 1) or were currently using a prescription medicine for BPH (Cohort 2) and who answered the purchase question in Part 1. (Age is missing for 8 men)

Age, Continuous
Age, Continuous(Years)Cohort 1Cohort 2Total
Mean61.8 ± 11.6768.3 ± 9.1063.0 ± 11.53
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female000
Male17313622093
08

Study locations

40 sites
  • Parkway Discount Drugs
    Birmingham, Alabama 35215, United States
  • Homewood Pharmacy
    Homewood, Alabama 35209, United States
  • Robert's Discount Pharmacy
    Hoover, Alabama 35226, United States
  • Pharmacy at the Pig
    McCalla, Alabama 35111, United States
  • Pinson Discount Drugs
    Pinson, Alabama 35126, United States
  • ACACIA Apothecary and Wellness
    Tucson, Arizona 85704, United States
  • Parkview Compounding Pharmacy
    Rancho Cucamonga, California 91730, United States
  • Garden Drug
    Fort Lauderdale, Florida 33309, United States
  • Pill Box Pharmacy
    Pembroke Pines, Florida 33026, United States
  • Sutton Family Pharmacy
    Dalton, Georgia 30721, United States
  • Huff's Drug Store
    Ellijay, Georgia 30540, United States
  • Wynn's Pharmacy Incorporated
    Griffin, Georgia 30224, United States
  • Family Care Pharmacy
    Highland, Illinois 62249, United States
  • Goodrich Pharmacy
    Andover, Minnesota 55304, United States
  • Goodrich Pharmacy
    Blaine, Minnesota 55434, United States
  • Goodrich Pharmacy
    Elk River, Minnesota 55330, United States
  • Northfield Pharmacy
    Northfield, Minnesota 55057, United States
  • Cub Pharmacy #1924
    Saint Louis Park, Minnesota 55426, United States
  • The Medicine Shoppe and Elsberry Pharmacy
    Elsberry, Missouri 63343, United States
  • Albers' Specialty Pharmacy
    Kansas City, Missouri 64111, United States
  • Apex Specialty Pharmacy
    Riverside, Missouri 64150, United States
  • Stevenson Family Pharmacy
    Saint Joseph, Missouri 64504, United States
  • Countryside Pharmacy
    Savannah, Missouri 64485, United States
  • Texas Road Pharmacy
    Monroe, New Jersey 08831, United States
  • Duran Central Pharmacy
    Albuquerque, New Mexico 87104, United States
  • Sam's Regent Pharmacy
    Albuquerque, New Mexico 87109, United States
  • Total Care Pharmacy
    Burlington, North Carolina 27215, United States
  • Kroger Pharmacy #342
    Cary, North Carolina 27513, United States
  • Charleston Pharmacy, South Charleston
    South Charleston, Ohio 45368, United States
  • Med Center Compounding Pharmacy & Health Center
    Cleveland, Tennessee 37311, United States
  • T.B. Bond Pharmacy
    Hillsboro, Texas 76645, United States
  • Eagle Pharmacy
    Houston, Texas 77099, United States
  • Mountain West Apothecary
    Bountiful, Utah 84010, United States
  • Maple Mountain Pharmacy
    Mapleton, Utah 84664, United States
  • The Medicine Shoppe
    Ogden, Utah 84401, United States
  • Family Plaza Pharmacy
    West Jordan, Utah 84088, United States
  • Foothills Compounding Pharmacy
    Enumclaw, Washington 98022, United States
  • Kelley-Ross Compounding Pharmacy
    Seattle, Washington 98104, United States
  • Rxtra Care
    Seattle, Washington 98115, United States
  • Kusler's Compounding Pharmacy
    Snohomish, Washington 98290, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Aug 2016, 10 months.

Results were first posted in Apr 2020, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2015
First posted
Oct 9, 2015
StartActual
Sep 23, 2015
Primary completionActual
Aug 1, 2016
CompletionActual
Aug 1, 2016
Results first posted
Apr 8, 2020
Last update
Apr 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02573311
Responsible party
Sponsor
First posted
Oct 9, 2015
Start date
Sep 23, 2015
Primary completion
Aug 1, 2016
Completion
Aug 1, 2016
Results posted
Apr 8, 2020
Last update
Apr 8, 2020

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion